- Home
- BTMD vs ZNTL Comparison
BTMD vs ZNTL Comparison
Compare BTMD & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTMD
- ZNTL
- Stock Information
- Founded
- BTMD 2012
- ZNTL 2014
- Country
- BTMD United States
- ZNTL United States
- Employees
- BTMD N/A
- ZNTL N/A
- Industry
- BTMD Medicinal Chemicals and Botanical Products
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- BTMD Health Care
- ZNTL Health Care
- Exchange
- BTMD Nasdaq
- ZNTL Nasdaq
- Market Cap
- BTMD 127.8M
- ZNTL 105.8M
- IPO Year
- BTMD N/A
- ZNTL 2020
- Fundamental
- Price
- BTMD $2.85
- ZNTL $1.76
- Analyst Decision
- BTMD Buy
- ZNTL Buy
- Analyst Count
- BTMD 2
- ZNTL 6
- Target Price
- BTMD $6.00
- ZNTL $6.53
- AVG Volume (30 Days)
- BTMD 114.6K
- ZNTL 686.7K
- Earning Date
- BTMD 11-11-2025
- ZNTL 11-11-2025
- Dividend Yield
- BTMD N/A
- ZNTL N/A
- EPS Growth
- BTMD 642.53
- ZNTL N/A
- EPS
- BTMD 0.88
- ZNTL N/A
- Revenue
- BTMD $199,073,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- BTMD N/A
- ZNTL N/A
- Revenue Next Year
- BTMD $4.85
- ZNTL N/A
- P/E Ratio
- BTMD $3.26
- ZNTL N/A
- Revenue Growth
- BTMD 6.32
- ZNTL N/A
- 52 Week Low
- BTMD $2.76
- ZNTL $1.01
- 52 Week High
- BTMD $6.98
- ZNTL $4.44
- Technical
- Relative Strength Index (RSI)
- BTMD 31.72
- ZNTL 62.41
- Support Level
- BTMD $2.82
- ZNTL $1.54
- Resistance Level
- BTMD $3.07
- ZNTL $1.69
- Average True Range (ATR)
- BTMD 0.12
- ZNTL 0.10
- MACD
- BTMD -0.01
- ZNTL 0.02
- Stochastic Oscillator
- BTMD 9.26
- ZNTL 94.03
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.